Abstract
The determination of anti-SARS-CoV-2 neutralizing antibodies (NAbs) is of interest in many respects. High NAb titers, for example, are the most important criterion regarding the effectiveness of convalescent plasma therapy. However, common cell culture-based NAb assays are time-consuming and feasible only in special laboratories. Our data reveal the suitability of a novel ELISA-based surrogate virus neutralization test (sVNT) to easily measure the inhibition-capability of NAbs in the plasma of COVID-19 convalescents. We propose a combined strategy to detect plasma samples with high NAb titers (≥ 1:160) reliably and to, simultaneously, reduce the risk of erroneously identifying low-titer specimens. For this approach, results of the sVNT assay are compared to and combined with those acquired from the Euroimmun anti-SARS-CoV-2 IgG assay. Both assays are appropriate for high-throughput screening in standard BSL-2 laboratories. Our measurements further show a long-lasting humoral immunity of at least 11 months after symptom onset.
Keywords: COVID-19; Detection of anti-SARS-CoV-2 neutralizing antibodies; Humoral immunity; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, Humoral immunity, Detection of anti-SARS-CoV-2 neutralizing antibodies, 【초록키워드】 neutralizing antibody, SARS-CoV-2, Neutralizing antibodies, risk, detection, anti-SARS-CoV-2, Convalescent plasma therapy, anti-SARS-CoV-2 IgG, virus neutralization test, neutralization test, Effectiveness, plasma, Neutralizing, specimens, surrogate virus neutralization test, NAb, symptom onset, NAbs, sVNT, plasma samples, criterion, NAb titers, NAb assays, approach, Cell, sVNT assay, NAb titer, plasma sample, BSL-2, detect, example, long-lasting, reduce, feasible, time-consuming, NAb assay, 【제목키워드】 anti-SARS-CoV-2, Laboratory, Neutralizing antibody titer, plasma sample, detect,